- Previous Close
2,090.00 - Open
2,085.00 - Bid 2,050.00 x --
- Ask 2,065.00 x --
- Day's Range
2,025.00 - 2,085.00 - 52 Week Range
1,775.00 - 3,490.00 - Volume
98,173 - Avg. Volume
1,241,458 - Market Cap (intraday)
77.168B - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Nov 13, 2024 - Nov 18, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Icure Pharmaceutical Incorporation, a biopharmaceutical company, researches, develops, and sells pharmaceutical and cosmetic products in South Korea. The company offers functional, nature-derived, derma, and customized cosmetics products. It also offers eye gel, hydro nude gel, lip gel mask, and functional patch products; and sheet, mud, foil, and melting masks. In addition, the company provides body and haircare products, including naturally derived hair and baby line, cleansing tissue, and wet wipes. Further, it offers perfumes, textile perfumes, body mists, and hair and body fragrances. Icure Pharmaceutical Incorporation was founded in 2000 and is based in Seoul, South Korea.
www.icure.co.kr202
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 175250.KQ
View MorePerformance Overview: 175250.KQ
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 175250.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 175250.KQ
View MoreValuation Measures
Market Cap
77.17B
Enterprise Value
144.31B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.30
Price/Book (mrq)
1.46
Enterprise Value/Revenue
2.41
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-50.67%
Return on Assets (ttm)
-9.64%
Return on Equity (ttm)
-42.05%
Revenue (ttm)
57.11B
Net Income Avi to Common (ttm)
-28.94B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
6.42B
Total Debt/Equity (mrq)
132.28%
Levered Free Cash Flow (ttm)
-5.34B